Patent 11744887 was granted and assigned to Arcturus Therapeutics on September, 2023 by the United States Patent and Trademark Office.
Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.